Literature DB >> 6282921

Multiple androgenic abnormalities, including elevated free testosterone, in hyperprolactinemic women.

S P Glickman, R L Rosenfield, R M Bergenstal, J Helke.   

Abstract

To investigate the basis of the hirsutism and elevated plasma dehydroepiandrosterone (DHA) and/or DHA sulfate (DHAS) in hyperprolactinemic women, we measured androgen binding parameters and an extensive profile of plasma androgens in normal (NL) and hyperprolactinemic women (HYPRL). ACTH tests and dexamethasone (dex) suppression tests were performed in subgroups. Free testosterone levels were higher in HYPRL (13.1 +/- 23.3 vs. 7.18 +/- 0.72 pg/ml; P less than 0.025), although total testosterone was comparable. This disparity was related to plasma testosterone-estradiol-binding globulin (TEBG) levels being one third lower in HYPRL (mean +/- SE, 27.4 +/- 4.0 nM) than in NL (41.2 +/- 3.7 nM; P less than 0.0125). Less striking elevations of plasma DHAS, androstenedione, and 11-deoxycortisol were found in HYPRL. Plasma total dihydrotestosterone [17 beta-hydroxy-5 alpha-androstan-3-one (tDHT)] was nearly 30% lower in HYPRL (11.2 +/- 2.6 ng/dl) than in NL (15.6 +/- 1.3 ng/dl; P less than 0.025), whereas free DHT was normal. Ratios of tDHT to precursors were lower in HYPRL (P less than 0.005). After ACTH stimulation, hyperresponsiveness of 17-hydroxyprogesterone and androstenedione were observed. Apparent adrenal enzyme efficiencies, judged from post-ACTH product to precursor ratios, were normal in HYPRL with one exception: the ratio of tDHT to total testosterone at 4 h was lower (P less than 0.05). Dex suppression normalized androgens and obliterated the abnormal tDHT to precursor ratios. These findings suggest an ACTH dependency of the abnormalities. In summary, we find that about 40% of HYPRL have an androgenic abnormality, and the most characteristic abnormality is an elevated free testosterone level (abnormal in 43%). Depressed TEBG and high DHAS levels were found with lesser frequency (19-21%). The plasma tDHT concentration was low, both in absolute terms and relative to its precursors. Dex suppressibility of the hyperandrogenemia was also observed. We postulate that PRL may exert multiple effects on steroid secretion and metabolism. Possibilities include the inhibition of the TEBG level.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282921     DOI: 10.1210/jcem-55-2-251

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Polycystic ovary syndrome in adolescence.

Authors:  Colleen Buggs; Robert L Rosenfield
Journal:  Endocrinol Metab Clin North Am       Date:  2005-09       Impact factor: 4.741

Review 2.  Hirsutism: evaluation and management.

Authors:  R E Watson; R Bouknight; P C Alguire
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

3.  Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients.

Authors:  E Carmina; F Rosato; A Jannì
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

Review 4.  [The sebaceous gland].

Authors:  C C Zouboulis
Journal:  Hautarzt       Date:  2010-06       Impact factor: 0.751

5.  Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C.

Authors:  W Urdl
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

Review 6.  Normal and Premature Adrenarche.

Authors:  Robert L Rosenfield
Journal:  Endocr Rev       Date:  2021-11-16       Impact factor: 19.871

7.  Direct relationship between elevated free testosterone and insulin resistance in hyperprolactinemic women.

Authors:  S Y Kim; Y A Sung; K S Ko; B Y Cho; H K Lee; C S Koh; H K Min
Journal:  Korean J Intern Med       Date:  1993-01       Impact factor: 2.884

Review 8.  Hormonal Effects on Hair Follicles.

Authors:  Monika Grymowicz; Ewa Rudnicka; Agnieszka Podfigurna; Paulina Napierala; Roman Smolarczyk; Katarzyna Smolarczyk; Blazej Meczekalski
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.